LOS ANGELES, CA, August 3, 2020 (GLOBE NEWSWIRE) – NEWMEDIAWIRE – US Nuclear Corp. (OTC: UCLE) aims to fight COVID-19 and help patients and survivors of the virus through MIFTEC to produce an unlimited source of cheap domestic medical isotopes
The IAEA supports more than 121 countries with RT-PCR equipment, which are used to stumble upon COVID-19 in real time using a nuclear energy-derived strategy and is one of the most accurate and widely used laboratory strategies. The Co-60 isotope is also used to sterilize medical equipment, appliances and materials for COVID-19 professionals to ensure their protection from use. Co-60 irradiation is one of the fastest and most effective strategies for sterilizing giant volumes of this equipment.
Medical isotopes and nuclear medicine are effective in sterilizing, detecting and combating COVID-19 and guiding the good fortune of treatment. In addition to damaging the patient’s lungs, the virus also attacks the heart, blood vessels, liver, intestines, brain and nervous system. Causes blood clots and strokes or seizures. Unfortunately, as a result, many of our COVID-19 survivors will want serious medical assistance for months or years.
Medical isotopes are used for pulmonary diagnosis, calculating the extent of the patient’s disease and mapping COVID-19 proteins, while others are being investigated as an imaginable remedy to combat severe cases of COVID-19. Medical isotopes are necessary for diagnostic tests in nuclear medicine to consult the doctor about the remedy of our brave survivors.
MIFTEC’s patented fusion isotope turbines will solve a number of problems:
Preparations are underway to build the MIFTEC Z-Pinch Fusion medical isotope turbines. Tests conducted through MIFTI at the Reno University’s National Terawatt Facility in 2018 using a 1 MegaAmp device produced a neutron greater than 1010, proving that their device was operating as expected. Then, a control is planned on L3 Harris’s four MegaAmp devices later this year. The U.S. Air Force’s MACH-2 simulation code predicts that this verification will seamlessly produce a neutron flow greater than 1012, or 1 trillion pulse-consistent neutrons—the amount required for radioisotope advertising production. MIFTI and MIFTEC have already developed plans for a 10 MegaAmp device, which is designed to provide significant net strength savings not only for medical isotopes, but also for power generation. US Nuclear is the exclusive manufacturer of MIFTEC medical isotope turbines in North America and Asia.
Safe Harbor Act
This press release includes “forward-looking statements” within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Actual effects would possibly differ from expectations, estimates, and projections, and therefore you do not rely on those forward-looking statements as long-term event predictions. Words such as “expect,” “estimate,” “project,” “budget,” “anticipate,” “anticipate,” “intend,” “plan,” “possibly,” “want,” “may also simply” “believe,” “predict,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant dangers and uncertainties that may also cause actual effects to differ materially from expected effects.
CONTACT: US Nuclear Corp. (OTC: UCLE) Robert I. Goldstein, President, CEO and President Rachel Boulds, CFO (818) 883 7043 Email: [email protected]